Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group
- 13 July 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 16 (1), 67-74
- https://doi.org/10.1007/s00520-007-0295-y
Abstract
Anemia is a common side effect of chemotherapy. Limited information exists about its incidence and risk factors. The objective of this study was to evaluate the incidence of anemia and risk factors for anemia occurrence in patients with early breast cancer who received adjuvant chemotherapy. We evaluated risk factors for anemia in pre- and post/perimenopausal patients with lymph node-positive early breast cancer treated with adjuvant chemotherapy in two randomized trials. All patients received four cycles of doxorubicin and cyclophosphamide (AC) followed by three cycles of cyclophosphamide, methotrexate, fluorouracil (CMF). Anemia incidence was related to baseline risk factors. Multivariable analysis used logistic and Cox regression. Among the 2,215 available patients, anemia was recorded in 11% during adjuvant chemotherapy. Grade 2 and 3 anemia occurred in 4 and 1% of patients, respectively. Pretreatment hemoglobin and white blood cells (WBC) were significant predictors of anemia. Adjusted odds ratios (logistic regression) comparing highest versus lowest quartiles were 0.18 (P < 0.0001) for hemoglobin and 0.52 (P = 0.0045) for WBC. Age, surgery type, platelets, body mass index, and length of time from surgery to chemotherapy were not significant predictors. Cox regression results looking at time to anemia were similar. Moderate or severe anemia is rare among patients treated with AC followed by CMF. Low baseline hemoglobin and WBC are associated with a higher risk of anemia.Keywords
This publication has 26 references indexed in Scilit:
- The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapySupportive Care in Cancer, 2006
- Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?Journal of Clinical Oncology, 2006
- Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast CancerJNCI Journal of the National Cancer Institute, 2006
- Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93Journal of Clinical Oncology, 2006
- Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinomaCancer, 2006
- Erythropoietin Biology in CancerClinical Cancer Research, 2006
- Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival StudyJournal of Clinical Oncology, 2005
- Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin ManagementThe Oncologist, 2005
- Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective surveyEuropean Journal Of Cancer, 2001
- Biological basis of anemiaSeminars in Oncology, 2001